{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:55:18Z","timestamp":1762624518543,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vaccine.2020.11.022","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T07:21:06Z","timestamp":1606029666000},"page":"8286-8291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Duration of seropositivity following yellow fever vaccination in U.S. military service members"],"prefix":"10.1016","volume":"38","author":[{"given":"Nicole P.","family":"Lindsey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabitha","family":"Woolpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad J.","family":"Biggerstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga I.","family":"Kosoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janeen J.","family":"Laven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewell M","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Staples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.022_b0005","series-title":"Vaccines","first-page":"1181","article-title":"Yellow fever vaccines","author":"Staples","year":"2018"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.022_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.022_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bjid.2017.02.004","article-title":"Yellow fever outbreak in Brazil, 2017","volume":"21","author":"Goldani","year":"2017","journal-title":"Braz J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.022_b0020","first-page":"1","article-title":"Centers for Disease Control and Prevention. Yellow fever vaccine: recommendations of the advisory committee on immunization practices","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.11.022_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0035-9203(36)90002-0","article-title":"Modification of the virulence of yellow fever virus by cultivation in tissues in vitro","volume":"29","author":"Lloyd","year":"1936","journal-title":"Trans R Soc Trop Med Hyg."},{"unstructured":"Courtois G. Time of appearance and duration of immunity conferred by 17D vaccine. In: Yellow Fever Vaccine. WHO Series. Geneva, Switzerland; 1956.","key":"10.1016\/j.vaccine.2020.11.022_b0030"},{"key":"10.1016\/j.vaccine.2020.11.022_b0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/oxfordjournals.aje.a121232","article-title":"Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans","volume":"93","author":"Monath","year":"1971","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.vaccine.2020.11.022_b0040","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine."},{"unstructured":"World Health Organization. International Health Regulations (2005). Switzerland. Available at: http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241580410_eng.pdf, Accessed February 19, 2020.","key":"10.1016\/j.vaccine.2020.11.022_b0045"},{"key":"10.1016\/j.vaccine.2020.11.022_b0050","first-page":"9","article-title":"Duration of immunity following yellow fever vaccination","volume":"34","author":"Courtois","year":"1954","journal-title":"Ann Soc Belg Med Trop."},{"key":"10.1016\/j.vaccine.2020.11.022_b0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4269\/ajtmh.1963.12.230","article-title":"Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine","volume":"12","author":"Rosenzweig","year":"1963","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.vaccine.2020.11.022_b0060","first-page":"699","article-title":"Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine","volume":"27","author":"Groot","year":"1962","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.vaccine.2020.11.022_b0065","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.vaccine.2020.11.022_b0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J Med Virol."},{"key":"10.1016\/j.vaccine.2020.11.022_b0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health."},{"key":"10.1016\/j.vaccine.2020.11.022_b0080","first-page":"206","article-title":"Long-term persistence of yellow fever neutralizing antibodies in persons aged 60 years and older","volume":"104","author":"Coulange Bodilis","year":"2011","journal-title":"Bull Soc Pathol Exot."},{"key":"10.1016\/j.vaccine.2020.11.022_b0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.2011.10-0496","article-title":"Description of a prospective 17DD yellow fever vaccine cohort in Recife","volume":"85","author":"de Melo","year":"2011","journal-title":"Brazil. Am J Trop Med Hyg."},{"issue":"39","key":"10.1016\/j.vaccine.2020.11.022_b0090","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","article-title":"Duration of post-vaccination immunity against yellow fever in adults","volume":"32","author":"Collaborative group for studies on yellow fever vaccines","year":"2014","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.vaccine.2020.11.022_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149871","article-title":"A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination","volume":"11","author":"Wieten","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.022_b0100","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946201759002","article-title":"Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults","volume":"59","author":"Miyaji","year":"2017","journal-title":"Rev Inst Med Trop Sao Paulo."},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.022_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J Travel Med."},{"issue":"11","key":"10.1016\/j.vaccine.2020.11.022_b0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/M18-1529","article-title":"Long-term protection after fractional-dose yellow fever vaccination: Follow-up study of a randomized, controlled, noninferiority trial","volume":"169","author":"Roukens","year":"2018","journal-title":"Ann Intern Med."},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.022_b0115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"Collaborative Group for Studies of Yellow Fever Vaccine. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil","volume":"25","author":"Campi-Azevedo","year":"2019","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.022_b0120","first-page":"[Epub]","article-title":"Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting","volume":"pii: jiz374","author":"Kareko","year":"2019","journal-title":"J Infect Dis."},{"unstructured":"World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013. Wkly Epidemiol Rec. 2013; 88(27): 269-283.","key":"10.1016\/j.vaccine.2020.11.022_b0125"},{"unstructured":"World Health Organization. International and Traveler Health: World \u2013 Yellow fever vaccination booster. 2014. Available at: http:\/\/www.who.int\/ith\/updates\/20140605\/en\/","key":"10.1016\/j.vaccine.2020.11.022_b0130"},{"unstructured":"Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE) for use of yellow fever vaccine booster doses. 2015. Available: https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/yf-vac-boost.html","key":"10.1016\/j.vaccine.2020.11.022_b0135"},{"key":"10.1016\/j.vaccine.2020.11.022_b0140","first-page":"647","article-title":"Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR."},{"key":"10.1016\/j.vaccine.2020.11.022_b0145","first-page":"796","article-title":"Yellow fever virus 17D neutralizing antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue","volume":"10","author":"Gomez","year":"2008","journal-title":"Rev Salud Publica."},{"doi-asserted-by":"crossref","unstructured":"Gibney KB, Edupuganti S, Panella AJ, et al. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3\u20134 years following yellow fever vaccination. Am J Trop Med Hyg. 2012; 87:1112\u20131115.","key":"10.1016\/j.vaccine.2020.11.022_b0150","DOI":"10.4269\/ajtmh.2012.12-0182"},{"key":"10.1016\/j.vaccine.2020.11.022_b0155","series-title":"Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections","first-page":"189","author":"Beaty","year":"1995"},{"issue":"14","key":"10.1016\/j.vaccine.2020.11.022_b0160","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the Design and Interpretation of Noninferiority Trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.022_b0165","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine."},{"issue":"S5","key":"10.1016\/j.vaccine.2020.11.022_b0170","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/civ603","article-title":"Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali","volume":"61","author":"Roy Chowdhury","year":"2015","journal-title":"Clin Infect Dis."},{"issue":"10","key":"10.1016\/j.vaccine.2020.11.022_b0175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12\u201313 months of age in Colombia and Peru: A randomized trial","volume":"35","author":"L\u00f3pez","year":"2016","journal-title":"Pediatr Infect Dis J."},{"doi-asserted-by":"crossref","unstructured":"de Noronha TG, de Lourdes de Sousa Maia M, Geraldo Leite Ribeiro J, et al.; Collaborative group for studies of yellow fever vaccine. Duration of post-vaccination humoral immunity against yellow fever in children. Vaccine. 2019; 37(48):7147-54.","key":"10.1016\/j.vaccine.2020.11.022_b0180","DOI":"10.1016\/j.vaccine.2019.09.051"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.022_b0185","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.022_b0190","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14760584.2019.1640118","article-title":"Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children","volume":"18","author":"Idoko","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2020.11.022_b0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CVI.00078-07","article-title":"Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus","volume":"15","author":"Niedrig","year":"2008","journal-title":"Clin Vaccine Immunol"},{"doi-asserted-by":"crossref","unstructured":"Camacho LA, da Silva Freire M, da Luz Fernandes Leal M, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38: 671-8.","key":"10.1016\/j.vaccine.2020.11.022_b0200","DOI":"10.1590\/S0034-89102004000500009"},{"key":"10.1016\/j.vaccine.2020.11.022_b0205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.022_b0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report","volume":"381","author":"Casey","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2020.11.022_b0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"npj Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:24Z","timestamp":1759402104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20314626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":43,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0264410X20314626"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of seropositivity following yellow fever vaccination in U.S. military service members","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}